Compare Amgen, Inc. (AMGN) vs Twilio Inc (TWLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Twilio Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Twilio Inc trades at $215.82 (market cap $32.56B). The key difference: Amgen, Inc. is far larger — about 6× Twilio Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| AMGN | TWLO | |
|---|---|---|
Market Cap | $196.12B | $32.56B |
Sector | Health | Technology |
52-Week High | $388.16 | $236.64 |
52-Week Low | $271.18 | $92.44 |
Enterprise Value | $241.41B | $31.29B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Twilio trades at $214.56, down 1.85% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows improving fundamentals with revenue growth to $5.07B in 2025 and a return to net profitability. Recent earnings beats and positive analyst sentiment, including a Goldman Sachs buy initiation at $300 (June 24, 2026), highlight momentum in AI-driven cloud communications.
Outlook remains positive given strong earnings beats and margin expansion potential, but high valuation multiples (P/E 325.09) pose risks if growth slows. Investors face execution risks in competitive SaaS markets and sensitivity to tech sector volatility. Wall Street consensus is bullish with 75% buy ratings and a $215.14 price target, near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
